Gilead’s third-quarter earnings beat by a wide margin, and biotech raises guidance

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.



Source link